Netanyahu allegedly to present Iran plan to Trump - Breaking The News

Netanyahu allegedly to present Iran plan to Trump

7 April

1 min read

EPA-EFE/YAIR SAGI

Israeli Prime Minister Benjamin Netanyahu plans to outline his vision of what "a good deal should look like" to US President Donald Trump during his upcoming White House meeting today, according to Axios, citing an Israeli official.

"Netanyahu wants the Libya model. Full dismantling of Iran's nuclear program", the official added.

Earlier, Axios had reported that US President Donald Trump had sent a message to Iran's Supreme Leader Ayatollah Ali Khamenei in March, establishing a two-month timeline for negotiating a new nuclear agreement.

Trump netanyahu us-iran relations us-israel relations israel-iran relations

Trump says will sign order to cut drug prices by 30-80%

5 hours ago

United States President Donald Trump announced that he would sign an executive order on Monday that will "almost immediately" reduce prescription drug and pharmaceutical prices by 30-80%. "They will rise throughout the World in order to equalize and, for the first time in many years, bring FAIRNESS TO AMERICA," Trump wrote on Truth Social. "I will be instituting a MOST FAVORED NATION’S POLICY whereby the United States will pay the same price as the...

Trump: Will announce pharma tariffs over next 2 weeks

5 May

United States President Donald Trump said that he has decided on the tariff rates for imports of pharmaceuticals and that he will announce them sometime "over the next two weeks." He offered no further details in his brief reply to a reporter's question in the Oval Office. Drugmakers have been bracing for levies similar to those on cars and aluminium, which stand at 25%, after Trump hinted as much last month.

Novartis to buy Regulus in deal worth up to $1.7B

30 April

Biopharmaceutical company Regulus Therapeutics Inc. announced on Wednesday it entered into an agreement to be acquired by Novartis AG in a deal worth up to $17. billionNovartis will make an initial payment of $7.00 per share, or a total of $0.8 billion, while Regulus shareholders will also receive "a contingent value right (CVR) providing for payment of $7.00 per share, contingent upon the achievement of a milestone with respect to regulatory approval...

GSK's Q1 sales up 2% to £7.5 billion

30 April

GSK plc announced on Wednesday its turnover in the first quarter of 2023 amounted to £6.95 billion, rising 2% from the same period in 2024. The increase at a constant exchange rate was 4%.Total earnings per share (EPS) soared 55% year on year to 39.7 pence, while core EPS rose 4% to 44.9 pence. Operating profit stood at £2.2 billion, rallying 49% from the first trimester of 2024, and adjusted operating profit climbed 4% to £2.5 billion."GSK continues...

This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.